Buffer solution, Solution A, Solution B, and Diluent— Prepare as directed in the Assay.

Standard solution— Use the Standard preparation, prepared as directed in the Assay.

System suitability stock solution— Weigh approximately 16 mg of Famotidine into a 50-mL volumetric flask, dissolve in 1.0 mL of 1 N hydrochloric acid, heat at 80 for 30 minutes, and cool to room temperature. Add 2.0 mL of 1 N sodium hydroxide, heat at 80 for 30 minutes, and cool to room temperature. Add 1.0 mL of 1 N hydrochloric acid to neutralize, and dilute with Diluent to volume.

System suitability solution— Weigh approximately 16 mg of Famotidine into a 50-mL volumetric flask, add 10 mL of Diluent, and sonicate to dissolve. Add 5 drops of hydrogen peroxide solution, heat at 80 for 15 minutes, and cool to room temperature. Add 20 mL of System suitability stock solution, and dilute with Diluent to volume.

Test solution— Use the Assay preparation, prepared as directed in the Assay.

Chromatographic system (see Chromatography 621)— Proceed as directed in the Assay, with the following addition. Chromatograph the System suitability solution, and identify the famotidine peak and the peaks due to impurities listed in Table 1. Record the peak responses as directed for Procedure: the resolution, R, between famotidine and impurity D is greater than 1.5.

Procedure— Separately inject equal volumes (about 20 µL) of the Standard solution and the Test solution into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in percentage, of the total of impurities C and D in the portion of Famotidine for Oral Suspension taken by the formula: in which CS is the concentration, in mg per mL, of USP Famotidine RS in the Standard solution; ru is the sum of the peak areas for impurities C and D obtained from the Test solution; and rS is the famotidine peak area obtained from the Standard solution: the total of impurities C and D is less than 2%.

(Official January 1, 2007)

Buffer solution— Dissolve 13.6 g of sodium acetate trihydrate in 900 mL of water, adjust with glacial acetic acid to a pH of 6.0 ± 0.1, and dilute with water to 1 L.

Solution A— Prepare a mixture of Buffer solution and acetonitrile (93:7).

Solution B— Use acetonitrile.

Diluent— Dissolve 13.6 g of monobasic sodium phosphate in 900 mL of water, adjust with 1 M sodium hydroxide to a pH of 7.0 ± 0.1, and dilute with water to 1 L. Mix 930 mL of this solution with 70 mL of acetonitrile.

Standard preparation— Dissolve an accurately weighed quantity of USP Famotidine RS in Diluent to obtain a solution having a known concentration of about 0.16 mg per mL.

Assay preparation— Transfer to a 100-mL volumetric flask an accurately measured portion of Famotidine for Oral Suspension, freshly mixed and free from air bubbles and constituted as directed in the labeling, equivalent to about 40 mg of famotidine, based on the labeled amount per mL of Famotidine for Oral Suspension. Add 10 mL of methanol, sonicate for 5 minutes, add 70 mL of Diluent, sonicate for an additional 5 minutes, and dilute with Diluent to volume. Dilute 10.0 mL of this solution with Diluent to 25.0 mL, and filter.

Chromatographic system (see Chromatography 621)— The liquid chromatograph is equipped with a 268-nm detector and a 4.6-mm × 25-cm column that contains 5-µm packing L1. The column temperature is maintained at 35. The flow rate is about 1.5 mL per minute. The chromatograph is programmed as follows. Chromatograph the Standard preparation, and record the peak responses as directed for Procedure: the tailing factor is not more than 2; the column efficiency is greater than 2000 theoretical plates; and the relative standard deviation for replicate injections is not more than 2.0%.

Procedure— Separately inject equal volumes (about 20 µL) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in mg, of famotidine (C8H15N7O2S3) in the portion of Famotidine for Oral Suspension taken by the formula: in which C is the concentration, in mg per mL, of USP Famotidine RS in the Standard preparation; D is the dilution factor, in mL, for famotidine in the Assay preparation; and rU and rS are the peak responses obtained from the Assay preparation and the Standard preparation, respectively.